CollPlant is a small Israeli biotech company developing regenerative medicine products based on its proprietary recombinant human Type I collagen (rhCollagen). CollPlant's core innovation is a plant-based production process that genetically engineers tobacco plants to express five human genes, producing collagen that CollPlant argues is structurally identical to naturally occurring human collagen and superior to animal-derived alternatives in purity and immunogenicity. Current revenue comes from two sources: milestone payments under a collaboration with AbbVie, and direct product sales of rhCollagen and bioink materials to research institutions and commercial partners. The AbbVie collaboration, focused on developing collagen-based dermal fillers, is the most financially significant program — CollPlant has received $26M in milestone payments to date and is eligible for up to $50M total, plus future royalties and supply fees if AbbVie commercializes a product. Direct product sales, including its Collink.3D bioinks and Collage rhCollagen solution, remain modest in scale. CollPlant's pipeline also includes a wholly owned photocurable dermal filler targeting facial volume restoration and a 3D-bioprinted regenerative breast implant designed to degrade and be replaced by native tissue — both are pre-clinical. CollPlant's broader strategy is to license rhCollagen and partner with large companies who fund development and commercialization, while CollPlant retains supply and royalty economics.